FDA Accepts BLA for Langlara by Sunshine Lake Pharma
The FDA has accepted the Biologics License Application for Langlara, an insulin glargine product from Sunshine Lake Pharma.
Asset / Drug
Drug and asset intelligence for Langlara with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.